BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 14742994)

  • 1. The fractional excretion of soluble interleukin-2 receptor-alpha is an excellent predictor of the interleukin-2 receptor-alpha status after treatment with daclizumab.
    ter Meulen CG; Jacobs CW; Wetzels JF; Klasen IS; Hilbrands LB; Hoitsma AJ
    Transplantation; 2004 Jan; 77(2):281-6. PubMed ID: 14742994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased renal excretion of soluble interleukin-2 receptor alpha after treatment with daclizumab.
    ter Meulen CG; Göertz JH; Klasen IS; Verweij CM; Hilbrands LB; Wetzels JF; Hoitsma AJ
    Kidney Int; 2003 Aug; 64(2):697-703. PubMed ID: 12846768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of an antibody against the soluble interleukin 2 receptor alpha subunit can modulate the stability and biodistribution of interleukin-2.
    Kobayashi H; Tagaya Y; Han ES; Kim IS; Le N; Paik CH; Pastan I; Nelson DL; Waldmann TA; Carrasquillo JA
    Cytokine; 1999 Dec; 11(12):1065-75. PubMed ID: 10623432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-2 receptor blockade in cardiac transplantation: influence of HLA-DR locus incompatibility on treatment efficacy.
    Lietz K; John R; Beniaminovitz A; Burke EM; Suciu-Foca N; Mancini DM; Edwards NM; Itescu S
    Transplantation; 2003 Mar; 75(6):781-7. PubMed ID: 12660501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD25 monoclonal antibody therapy affects the death signals of graft-infiltrating cells after clinical heart transplantation.
    Baan CC; Balk AH; van Riemsdijk IC; Vantrimpont PJ; Maat AP; Niesters HG; Zondervan PE; van Gelder T; Weimar W
    Transplantation; 2003 May; 75(10):1704-10. PubMed ID: 12777860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis.
    Krueger JG; Walters IB; Miyazawa M; Gilleaudeau P; Hakimi J; Light S; Sherr A; Gottlieb AB
    J Am Acad Dermatol; 2000 Sep; 43(3):448-58. PubMed ID: 10954656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of thyroxine on serum soluble interleukin-2 receptor alpha levels in thyroid disorders.
    Zwirska-Korczala K; Berdowska A; Jochem J; Sitkiewicz A; Birkner E; Polaniak R; Jedrzejowska-Szypułka H; Korzonek-Szlacheta I
    J Clin Pharm Ther; 2004 Apr; 29(2):151-6. PubMed ID: 15068404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of soluble interleukin-2 receptor alpha (sIL-2Ralpha) as a predictor of outcome in brucellosis.
    Makis AC; Galanakis E; Hatzimichael EC; Papadopoulou ZL; Siamopoulou A; Bourantas KL
    J Infect; 2005 Oct; 51(3):206-10. PubMed ID: 16230217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients.
    Morris JA; Hanson JE; Steffen BJ; Chu AH; Chi-Burris KS; Gotz VP; Gordon RD
    Clin Transplant; 2005 Jun; 19(3):340-5. PubMed ID: 15877795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation.
    Koch M; Niemeyer G; Patel I; Light S; Nashan B
    Transplantation; 2002 May; 73(10):1640-6. PubMed ID: 12042653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble interleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer: prognostic value and analysis of their relationships.
    El Houda Agueznay N; Badoual C; Hans S; Gey A; Vingert B; Peyrard S; Quintin-Colonna F; Ravel P; Bruneval P; Roncelin S; Lelongt B; Bertoglio J; Fridman WH; Brasnu D; Tartour E
    Clin Exp Immunol; 2007 Oct; 150(1):114-23. PubMed ID: 17680822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis of immunosuppression by the therapeutic antibody daclizumab.
    Yang H; Wang J; Du J; Zhong C; Zhang D; Guo H; Guo Y; Ding J
    Cell Res; 2010 Dec; 20(12):1361-71. PubMed ID: 20820193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methods to avoid adverse effect of circulating antigen on biodistribution of 125I-labeled antiTac dsFv: preinjection of intact antibody versus clearance of antigen with adivin-biotin system.
    Kobayashi H; Sun BF; Yoo TM; Le N; Kim MK; Paik CH; Pastan I; Waldmann TA; Carrasquillo JA
    J Nucl Med; 1999 Aug; 40(8):1381-91. PubMed ID: 10450692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience with single-dose daclizumab in the prevention of acute rejection in heart transplantation.
    Cuppoletti A; Perez-Villa F; Vallejos I; Roig E
    Transplant Proc; 2005 Nov; 37(9):4036-8. PubMed ID: 16386620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring of T-cell subsets in patients treated with anti-CD 25 antibody.
    Praditpornsilpa K; Avihingsanon Y; Kupatawintu P; Songpanich S; Pisitkul T; Kansanabuch T; Eiam-Ong S; Chusil S; O-Charoen R; Tungsanga K
    Transplant Proc; 2004 Mar; 36(2 Suppl):487S-491S. PubMed ID: 15041394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice?
    Van Gelder T; Warlé M; Ter Meulen RG
    Drugs; 2004; 64(16):1737-41. PubMed ID: 15301558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids.
    Kobashigawa J; David K; Morris J; Chu AH; Steffen BJ; Gotz VP; Gordon RD
    Transplant Proc; 2005 Mar; 37(2):1333-9. PubMed ID: 15848713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble interleukin 2 receptor (sIL-2R) levels in renal transplant recipients.
    Mehta R; Shah G; Adler W; Kittur D
    Clin Transplant; 2004; 18 Suppl 12():67-71. PubMed ID: 15217411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
    Cheung CY; Liu YL; Wong KM; Chan HW; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Shek CC; Li CS
    Nephrology (Carlton); 2008 Jun; 13(3):251-5. PubMed ID: 18221256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High urine sIL-6R as a predictor of late graft failure in renal transplant recipients.
    Sadeghi M; Daniel V; Wiesel M; Hergesell O; Opelz G
    Transplantation; 2003 Oct; 76(8):1190-4. PubMed ID: 14578752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.